Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and depression in adults with type 2 diabetes mellitus living at high altitude
ChiCTR2400084738Phase 4Not yet recruiting
- Sponsor
- People's Hospital of Tibet Autonomous Region
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD) (2 arms), sponsored by People's Hospital of Tibet Autonomous Region. Primary endpoint: 17-item Hamilton Depression Rating Scale. Planned start May 2024; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400084738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084738.